![]() | |
| 公司名 | BOC Sciences |
| 联系人 | Linna Green |
| 电 话 | +16314854226 |
| 手 机 | +16314854226 |
| 电子邮件 | info@bocsci.com |
| 网 址 | http://www.bocsci.com/ |
| 地 区 | 其他 |
| 邮 编 | 11967 |
在线询盘仅适合非紧急采购的情形,您需要留下收货地域,采购数量及联系方式。供应商在收到您的询盘信息后,会通过您留下的联系方式联络您。如果您希望立即和供应商交谈,请直接拨打供应商电话。供应商手机:+16314854226
| 中文名 | PHA-848125 |
| 英文名 | PHA-848125 |
| 别名 | 化合物MILCICLIB;MILCICLIB (PHA-848125)抑制剂;4,5-二氢-N,1,4,4-四甲基-8-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-1H-吡唑并[4,3-H]喹唑啉-3-甲酰胺;N,1,4,4-四甲基-8-((4-(4-甲基哌嗪-1-基)苯基)氨基)-4,5-二氢-1H-吡唑并[4,3-H]喹唑啉-3-甲酰胺 |
| CAS | 802539-81-7 |
| EINECS | |
| 化学式 | C25H32N8O |
| 分子量 | 460.57 |
| inchi | |
| 包装信息 | 5 mg |
| 价格 | $197 |
| 产品描述 | PHA-848125 Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types. |
| 产品链接 | http://www.bocsci.com/product/milciclib-cas-802539-81-7-459709.html |
| 更新日期 | 2025-04-30 11:27:47 |